Rising incidence trends of synchronous prostate and rectal cancers: a population-based study
DOI:
https://doi.org/10.2340/1651-226X.2025.42592Keywords:
Prostate Cancer, Rectal cancer, Cancer Registry, Cancer epidemiologyAbstract
Background: There is a lack of comprehensive reports on time trends in synchronous prostate and rectal cancers. To address this, we conducted the largest cohort study to date to assess these trends in a population-based setting.
Methods: We included all adult (ages 18−99) men with incident prostate cancer in the Swedish Cancer Register in 1993−2019. Age-standardized incidence rates (ASIRs) of prostate cancer per 100,000 male population per year were calculated and compared to the ASIR of synchronous (± 6 months from rectal cancer diagnosis) prostate cancer. Age-adjusted synchronous-to-general incidence rate ratios (IRRs) were predicted using Poisson regression. As a sensitivity analysis to assess the effect of incidental findings due to the anatomical proximity, we investigated synchronous prostate and non-sigmoid colon cancers.
Results: Among 238,252 prostate cancer cases, 594 were synchronous with rectal cancer. The incidence of synchronous prostate cancer increased over the study period, with mean ASIR rising from 418/100,000 (1993−2001) to 788/100,000 (year 2011−2019). The synchronous-to-general IRR increased from 1.92 (95% confidence interval (CI) 1.60−2.31) to 2.61 (95% CI 2.32−2.95) over the same periods. Prostate cancer was also more commonly diagnosed in conjunction with non-sigmoid colon cancer than in the overall male population, but no time trend was observed.
Interpretation: The incidence of synchronous prostate and rectal cancers has increased over the past 20 years in Sweden, with no signs of plateauing. Future studies are warranted to explore factors contributing to prostate cancer overdiagnosis and to optimize clinical management strategies for this complex patient group.
Downloads
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
https://doi.org/10.3322/caac.21660 DOI: https://doi.org/10.3322/caac.21660
Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on prostate cancer epidemiology and risk factors – a systematic review. Eur Urol. 2023;84:191–206.
https://doi.org/10.1016/j.eururo.2023.04.021 DOI: https://doi.org/10.1016/j.eururo.2023.04.021
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16:713–32.
https://doi.org/10.1038/s41575-019-0189-8 DOI: https://doi.org/10.1038/s41575-019-0189-8
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–54.
https://doi.org/10.3322/caac.21772 DOI: https://doi.org/10.3322/caac.21772
Fernandes MC, Gollub MJ, Brown G. The importance of MRI for rectal cancer evaluation. Surg Oncol. 2022;43:101739.
https://doi.org/10.1016/j.suronc.2022.101739 DOI: https://doi.org/10.1016/j.suronc.2022.101739
Stabile A, Giganti F, Rosenkrantz AB, Taneja SS, Villeirs G, Gill IS, et al. Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nat Rev Urol. 2020;17:41–61.
https://doi.org/10.1038/s41585-019-0212-4 DOI: https://doi.org/10.1038/s41585-019-0212-4
Jacobs CD, Trotter J, Palta M, Moravan MJ, Wu Y, Willett CG, et al. Multi-institutional analysis of synchronous prostate and rectosigmoid cancers. Front Oncol. 2020;10:345.
https://doi.org/10.3389/fonc.2020.00345 DOI: https://doi.org/10.3389/fonc.2020.00345
Sharp HJ, Swanson DA, Pugh TJ, Zhang M, Phan J, Kudchadker R, et al. Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Pract Radiat Oncol. 2012;2:e7–13.
https://doi.org/10.1016/j.prro.2011.11.010 DOI: https://doi.org/10.1016/j.prro.2011.11.010
Terris MK, Wren SM. Results of a screening program for prostate cancer in patients scheduled for abdominoperineal resection for colorectal pathologic findings. Urology. 2001;57:943–5.
https://doi.org/10.1016/S0090-4295(01)00943-8 DOI: https://doi.org/10.1016/S0090-4295(01)00943-8
Enblad P, Adami HO, Glimelius B, Krusemo U, Påhlman L. The risk of subsequent primary malignant diseases after cancers of the colon and rectum. A nationwide cohort study. Cancer. 1990;65:2091–100. DOI: https://doi.org/10.1002/1097-0142(19900501)65:9<2091::AID-CNCR2820650934>3.0.CO;2-M
https://doi.org/10.1002/1097-0142(19900501)65:9%3C2091::AID-CNCR2820650934%3E3.0.CO;2-M
Sturludóttir M, Martling A, Carlsson S, Blomqvist L. Synchronous rectal and prostate cancer – the impact of MRI on incidence and imaging findings. Eur J Radiol. 2015;84:563–7.
https://doi.org/10.1016/j.ejrad.2014.12.030 DOI: https://doi.org/10.1016/j.ejrad.2014.12.030
Seretis C, Seretis F, Liakos N. Multidisciplinary approach to synchronous prostate and rectal cancer: current experience and future challenges. J Clin Med Res. 2014;6:157–61.
https://doi.org/10.14740/jocmr1796w DOI: https://doi.org/10.14740/jocmr1796w
Doussot A, Vernerey D, Rullier E, Lefevre JH, Meillat H, Cotte E, et al. Surgical management and outcomes of rectal cancer with synchronous prostate cancer: a multicenter experience from the GRECCAR group. Ann Surg Oncol. 2020;27:4286–93.
https://doi.org/10.1245/s10434-020-08683-4 DOI: https://doi.org/10.1245/s10434-020-08683-4
Lakkis Z, Vernerey D, Mege D, Faucheron JL, Panis Y, Tuech JJ, et al. Morbidity and oncological outcomes of rectal cancer impaired by previous prostate malignancy. Br J Surg. 2019;106:1087–98.
https://doi.org/10.1002/bjs.11176 DOI: https://doi.org/10.1002/bjs.11176
Guandalino M, Dupré A, François M, Leroy B, Antomarchi O, Buc E, et al. Previous radiation for prostate neoplasm alters surgical and oncologic outcomes after rectal cancer surgery. J Surg Oncol. 2015;112:802–8.
https://doi.org/10.1002/jso.24075 DOI: https://doi.org/10.1002/jso.24075
Tomminen T, Huhtala H, Kotaluoto S, Veitonmäki T, Wirta EV, Hyöty M. Surgical and oncological results after rectal resections with or without previous treatment for prostate cancer. Front Surg. 2024;11:1298865.
https://doi.org/10.3389/fsurg.2024.1298865 DOI: https://doi.org/10.3389/fsurg.2024.1298865
Nash GF, Turner KJ, Hickish T, Smith J, Chand M, Moran BJ. Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum. Ann R Coll Surg Engl. 2012;94:456–62.
https://doi.org/10.1308/003588412X13373405384611 DOI: https://doi.org/10.1308/003588412X13373405384611
Celentano G, Creta M, Napolitano L, Abate M, La Rocca R, Capece M, et al. Prostate cancer diagnosis, treatment and outcomes in patients with previous or synchronous colorectal cancer: a systematic review of published evidence. Diagnostics (Basel). 2022;12(6):1475.
https://doi.org/10.3390/diagnostics12061475 DOI: https://doi.org/10.3390/diagnostics12061475
Vallancien G, Cathelineau X, Baumert H, Doublet JD, Guillonneau B. Complications of transperitoneal laparoscopic surgery in urology: review of 1,311 procedures at a single center. J Urol. 2002;168:23–6.
https://doi.org/10.1016/S0022-5347(05)64823-9 DOI: https://doi.org/10.1016/S0022-5347(05)64823-9
Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48:27–33.
https://doi.org/10.1080/02841860802247664 DOI: https://doi.org/10.1080/02841860802247664
Pan SY, Huang CP, Chen WC. Synchronous/metachronous multiple primary malignancies: review of associated risk factors. Diagnostics (Basel). 2022;12(3):1940.
https://doi.org/10.3390/diagnostics12081940 DOI: https://doi.org/10.3390/diagnostics12081940
Rezende LFM, Sa TH, Markozannes G, Rey-Lopez JP, Lee IM, Tsilidis KK, et al. Physical activity and cancer: an umbrella review of the literature including 22 major anatomical sites and 770 000 cancer cases. Br J Sports Med. 2018;52:826–33.
https://doi.org/10.1136/bjsports-2017-098391 DOI: https://doi.org/10.1136/bjsports-2017-098391
Bowrey DJ, Otter MI, Billings PJ. Rectal infiltration by prostatic adenocarcinoma: report on six patients and review of the literature. Ann R Coll Surg Engl. 2003;85:382–5.
https://doi.org/10.1308/003588403322520726 DOI: https://doi.org/10.1308/003588403322520726
Kavanagh DO, Quinlan DM, Armstrong JG, Hyland JM, O’Connell PR, Winter DC. Management of synchronous rectal and prostate cancer. Int J Colorectal Dis. 2012;27:1501–8.
https://doi.org/10.1007/s00384-012-1465-z DOI: https://doi.org/10.1007/s00384-012-1465-z
NPCR. ”MR först” Hur går det? Nyheter 2021 [cited 2025 February 6]; Available from: https://npcr.se/mr-forst-hur-gar-det/
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403:1027–50.
Arnold M, Pandeya N, Byrnes G, Renehan PAG, Stevens GA, Ezzati PM, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16:36–46.
https://doi.org/10.1016/S1470-2045(14)71123-4 DOI: https://doi.org/10.1016/S1470-2045(14)71123-4
Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer – viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794–8.
https://doi.org/10.1056/NEJMsr1606602 DOI: https://doi.org/10.1056/NEJMsr1606602
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Elias Edfelt, Mehrnoosh Shahrivar, Karin Holmsten, Cecilia Radkiewicz
This work is licensed under a Creative Commons Attribution 4.0 International License.
